This comprehensive training program is designed to provide pharmaceutical professionals with an in-depth understanding of the regulatory requirements, scientific principles, and practical strategies for preparing and submitting Abbreviated New Drug Applications (ANDAs) to the U.S. Food and Drug Administration (FDA). The program incorporates the latest regulatory developments under the Generic Drug User Fee Amendments (GDUFA III), covering fiscal years 2023-2027, and reflects FDA’s current thinking on generic drug development and approval pathways as of June 2026.

The program is built upon the foundational principle that generic drugs must be pharmaceutically equivalent, bioequivalent, and therapeutically equivalent to their Reference Listed Drug (RLD), ensuring that the generic product can be substituted with the full expectation that it will produce the same clinical effect and safety profile as the RLD under the conditions specified in the labeling.

PROGRAM OBJECTIVES

Upon completion of this program, participants will be able to:

• Understand the legislative and regulatory framework governing generic drug approvals, including the Hatch-Waxman Act and its amendments, and the statutory authority under section 505(j) of the Federal Food, Drug, and Cosmetic Act
• Navigate the FDA’s Orange Book to identify Reference Listed Drugs (RLDs), patent information, therapeutic equivalence evaluations, exclusivity periods, and Reference Standards for bioequivalence studies
• Design and interpret bioequivalence (BE) studies using pharmacokinetic endpoints in accordance with 21 CFR Part 320 and FDA guidance documents, including Product-Specific Guidances
• Prepare and submit a complete ANDA, including Chemistry, Manufacturing, and Controls (CMC), labeling, and bioequivalence sections in the required format
• Apply patent certification strategies, including Paragraph IV certifications, notice requirements, and 180-day exclusivity provisions, while managing the complexities of patent litigation and 30-month stays
• Engage effectively with FDA through the Pre-ANDA program, controlled correspondence, Product-Specific Guidance (PSG) meetings, and formal interactions
• Manage post-approval changes and maintain compliance throughout the product lifecycle, including SUPAC-IR and SUPAC-MR requirements
• Implement data integrity principles and quality metrics in generic drug development, ensuring compliance with CGMP requirements
• Navigate complex product development pathways, including drug-device combination products, complex generics, and products requiring comparative use human factors studies
• Develop strategic approaches to ANDA development, including risk assessment, timeline management, and resource allocation

PROGRAM SCOPE

This training program covers the full spectrum of ANDA-related topics, from foundational regulatory knowledge to advanced strategic considerations. The scope includes:

Regulatory Framework

• Hatch-Waxman Amendments and the evolution of generic drug legislation
• Section 505(j) of the FD&C Act and implementing regulations
• GDUFA III performance goals and program enhancements
• FDA organizational structure and the role of the Office of Generic Drugs

Orange Book and Reference Listed Drug Selection

• Structure and content of the Orange Book
• Therapeutic equivalence codes and their significance
• RLD selection criteria and strategies
• Patent and exclusivity information interpretation

Bioequivalence Science and Study Design

• Pharmacokinetic principles and parameters
• Study design considerations (crossover, parallel, replicate)
• Statistical approaches (average BE, reference-scaled BE)
• BCS-based biowaivers and in vitro alternatives
• Product-Specific Guidances (PSGs) and their application

Chemistry, Manufacturing, and Controls (CMC)

• Drug substance characterization and specifications
• Drug product formulation and manufacturing
• Inactive ingredient considerations
• Container closure systems and extractables/leachables
• Stability studies and shelf-life determination
• Drug Master Files (DMFs) and right of reference

Labeling Requirements

• “Same as” standard and permissible differences
• Labeling components (prescribing information, patient labeling, container labeling)
• Labeling review process and annotated labeling
• Post-approval labeling updates

Patent Certification and Exclusivity

• Orange Book patent listing system
• Patent certification types (Paragraphs I-IV)
• Paragraph IV certification procedures and notice requirements
• 180-day exclusivity eligibility and forfeiture
• Patent litigation and 30-month stays
• Suitability petitions under 21 CFR 314.93

Pre-ANDA and FDA Engagement

• Controlled correspondence procedures
• Pre-ANDA meeting types and preparation
• Product-Specific Guidance meetings
• Formal dispute resolution

Post-Approval Changes and Lifecycle Management

• SUPAC-IR and SUPAC-MR guidances
• Reporting categories (major, moderate, minor changes)
• Supplements and annual reports
• Postmarketing reporting of adverse drug experiences

Data Integrity and Quality Metrics

• Data integrity principles (ALCOA)
• CGMP requirements for electronic records
• Audit trail review and management
• Quality metrics program

Complex Generic Products

• Drug-device combination products
• Comparative use human factors studies
• Complex active ingredients and formulations
• Locally acting drugs and topical products

TARGET AUDIENCE

This program is designed for professionals working in or transitioning to roles involving generic drug development and ANDA submissions. The content is appropriate for both early-career professionals seeking foundational knowledge and experienced professionals requiring updates on current regulatory requirements and best practices.

Primary Target Audiences:

Regulatory Affairs Professionals

• Regulatory Affairs Associates, Managers, and Directors
• Regulatory Strategy Specialists
• Submission Managers and Coordinators
• Labeling Specialists

Pharmaceutical Development and Formulation Scientists

• Formulation Scientists and Engineers
• Product Development Managers
• Process Development Scientists
• Scale-up and Technical Transfer Specialists

Quality Assurance/Quality Control Professionals

• Quality Assurance Managers and Directors
• Quality Control Managers
• QA/QC Scientists and Analysts
• Compliance Specialists
• Auditors (internal and external)

Clinical Pharmacology and Bioequivalence Specialists

• Clinical Pharmacologists
• Bioequivalence Study Managers
• Clinical Research Scientists
• Pharmacokineticists

Chemistry, Manufacturing, and Controls (CMC) Specialists

• CMC Regulatory Affairs Specialists
• Analytical Development Scientists
• Stability Study Managers
• Analytical Method Validation Specialists

Project Management Professionals

• Project Managers in Pharmaceutical Development
• Program Managers
• Portfolio Managers

Contract Research Organization (CRO) and Contract Manufacturing Organization (CMO) Personnel

• Business Development Professionals
• Study Directors
• Project Managers
• Regulatory Affairs Specialists

Legal and Intellectual Property Professionals

• Patent Attorneys
• Intellectual Property Counsel
• Regulatory Attorneys

Level of Experience:

• Beginner: 0-2 years of experience in pharmaceutical industry (foundational modules)
• Intermediate: 2-5 years of experience (comprehensive modules)
• Advanced: 5+ years of experience (strategic workshops and case studies)

CERTIFICATION REQUIREMENTS

Upon successful completion of the program, participants will be awarded a Certificate of Completion in ANDA Regulatory Strategy and Submission. This credential is issued upon fulfillment of the program requirements outlined below.

Certificate Attributes

The certificate is 21 CFR Part 11 compliant and issued in a secure, tamper-evident digital format, ensuring data integrity, authenticity, and traceability. It is designed for global regulatory recognition and acceptance, aligned with widely adopted industry training and compliance standards.